Research across borders

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find studies Explore world registries Peptide directory

Find a study

Enter a peptide, product, condition or location. Try generic names, brand names and development codes separately. Results are registry search matches, not automatically verified links to a WPF peptide record.

Search terms are sent to ClinicalTrials.gov and appear in the page URL. Do not enter personal or medical identifying information. Registry records are served with up to a one-hour cache; registry updates themselves can lag real-world changes.

Registry search results

Matching records; showing 20 on this page, newest registry updates first. Search checked 2026-11-08 21:13 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Phase 2CompletedINTERVENTIONAL

Chemotherapy, Hormone Therapy, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer

ClinicalTrials.gov · NCT00016913 · Registry updated: 2016-07-06

Condition / research focus: Prostate Cancer
Sponsor: Alliance for Clinical Trials in Oncology
Countries with listed sites: United States
Registry dates and results: Start: 2001-05. Completion: 2008-05 (may be estimated). Results are posted in this registry.

Products and interventions (5)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

carboplatin (drug)
estramustine (drug)
paclitaxel (drug)
radiation therapy (radiation)
leuprolide or goserelin acetate (drug)

Where the study takes place — 23 listed sites

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

Lombardi Comprehensive Cancer Center at Georgetown University Medical Center
Washington D.C., District of Columbia, United States
Site recruitment: Not reported
Walter Reed Army Medical Center
Washington D.C., District of Columbia, United States
Site recruitment: Not reported
Greenebaum Cancer Center at University of Maryland Medical Center
Baltimore, Maryland, United States
Site recruitment: Not reported
Veterans Affairs Medical Center - Baltimore
Baltimore, Maryland, United States
Site recruitment: Not reported
UMASS Memorial Cancer Center - University Campus
Worcester, Massachusetts, United States
Site recruitment: Not reported
Saint Luke's Hospital
Chesterfield, Missouri, United States
Site recruitment: Not reported
University Medical Center of Southern Nevada
Las Vegas, Nevada, United States
Site recruitment: Not reported
CCOP - Nevada Cancer Research Foundation
Las Vegas, Nevada, United States
Site recruitment: Not reported
Memorial Sloan-Kettering Cancer Center
New York, New York, United States
Site recruitment: Not reported
Oswego Hospital
Oswego, New York, United States
Site recruitment: Not reported
CCOP - Hematology-Oncology Associates of Central New York
Syracuse, New York, United States
Site recruitment: Not reported
SUNY Upstate Medical University Hospital
Syracuse, New York, United States
Site recruitment: Not reported
Veterans Affairs Medical Center - Syracuse
Syracuse, New York, United States
Site recruitment: Not reported
Community General Hospital of Greater Syracuse
Syracuse, New York, United States
Site recruitment: Not reported
Wayne Memorial Hospital, Incorporated
Goldsboro, North Carolina, United States
Site recruitment: Not reported
Wayne Radiation Oncology
Goldsboro, North Carolina, United States
Site recruitment: Not reported
Lenoir Memorial Cancer Center
Kinston, North Carolina, United States
Site recruitment: Not reported
Wilson Medical Center
Wilson, North Carolina, United States
Site recruitment: Not reported
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University
Columbus, Ohio, United States
Site recruitment: Not reported
Roper St. Francis Cancer Center at Roper Hospital
Charleston, South Carolina, United States
Site recruitment: Not reported
Bon Secours St. Francis Health System
Greenville, South Carolina, United States
Site recruitment: Not reported
CCOP - Greenville
Greenville, South Carolina, United States
Site recruitment: Not reported
Danville Regional Medical Center
Danville, Virginia, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableWithdrawnINTERVENTIONAL

Down-regulated Hormonally Controlled Cycles for Vitrification-warmed Blastocyst Transfers

ClinicalTrials.gov · NCT02238431 · Registry updated: 2016-05-26

Condition / research focus: Pregnancy
Sponsor: Antalya IVF
Countries with listed sites: Turkey (Türkiye)
Registry dates and results: Start: 2014-12. Completion: 2016-06 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Lucrin depot (drug)
OCP (drug)
Natural (other)

Where the study takes place — 1 listed sites

Antalya IVF
Antalya, Antalya, Turkey (Türkiye)
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

Everolimus, Bicalutamide, and Leuprolide Acetate in Treating Patients Undergoing Radiation Therapy For High-Risk Locally Advanced Prostate Cancer

ClinicalTrials.gov · NCT00943956 · Registry updated: 2016-05-25

Condition / research focus: Prostate Cancer
Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle
Countries with listed sites: France
Registry dates and results: Start: 2009-01. Completion: 2012-12 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

bicalutamide (drug)
everolimus (drug)
leuprolide acetate (drug)
external beam radiation therapy (radiation)

Where the study takes place — 1 listed sites

Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle
Montpellier, France
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

COmbining Oral Letrozole and Clomiphene for Ovarian Stimulation (COOL-COS) Associated With Corifollitropin Alfa: a Pilot Study

ClinicalTrials.gov · NCT02448459 · Registry updated: 2016-05-23

Condition / research focus: Infertility
Sponsor: University of Sao Paulo
Countries with listed sites: Brazil
Registry dates and results: Start: 2015-05. Completion: 2016-05 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

COOL-COS (drug) — also listed as: Friendly COS

Where the study takes place — 1 listed sites

Setor de Reprodução Humana - HC-FMRP-USP
Ribeirão Preto, São Paulo, Brazil
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Anastrazole Plus GnRH-agonist in the Treatment of Endometriosis Recurrence

ClinicalTrials.gov · NCT01769781 · Registry updated: 2016-04-27

Condition / research focus: Endometriosis
Sponsor: Centre for Endocrinology and Reproductive Medicine, Italy
Countries with listed sites: Italy
Registry dates and results: Start: 2013-01. Completion: 2015-07 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

anastrazole (drug)
GnRH analog alone (drug)

Where the study takes place — 1 listed sites

Cerm-Hungaria
Rome, Italy
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4TerminatedINTERVENTIONAL

Comparison of Trelstar Versus Lupron or Zoladex in Advanced Prostate Cancer

ClinicalTrials.gov · NCT02749825 · Registry updated: 2016-04-25

Condition / research focus: Prostate Cancer
Sponsor: Pharmatech
Countries with listed sites: United States
Registry dates and results: Start: 2002-09. Completion: 2006-07 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Trelstar (drug) — also listed as: Triptorelin pamoate
Lupron (drug) — also listed as: luprolide acetate for depot suspension
Zoladex (drug) — also listed as: goserelin acetate

Where the study takes place — 11 listed sites

Arizona Urologic Specialists
Tucson, Arizona, United States
Site recruitment: Not reported
Heritage Physician Group - Urology Department
Hot Springs, Arkansas, United States
Site recruitment: Not reported
California Oncology of the Central Valley
Fresno, California, United States
Site recruitment: Not reported
San Bernardino Urological Associates Medical Group
San Bernardino, California, United States
Site recruitment: Not reported
UroSearch
Ocala, Florida, United States
Site recruitment: Not reported
Scott A Slavis, MD, PC
Las Vegas, Nevada, United States
Site recruitment: Not reported
Shaukat M Qureshi, MD
Pennsville, New Jersey, United States
Site recruitment: Not reported
Brooklyn Heights Urology Associates
Brooklyn, New York, United States
Site recruitment: Not reported
Jazrawi-Atallah, P.C.
Brooklyn, New York, United States
Site recruitment: Not reported
Albemarle Urology Clinic, PA
Albemarle, North Carolina, United States
Site recruitment: Not reported
Raj P. Chopra MD, PC
Bloomsburg, Pennsylvania, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Extended Endocrine Therapy for Premenopausal Women With Breast Cancer

ClinicalTrials.gov · NCT00903162 · Registry updated: 2016-04-18

Condition / research focus: Breast Cancer
Sponsor: Dana-Farber Cancer Institute
Countries with listed sites: United States
Registry dates and results: Start: 2009-05. Completion: 2014-09 (may be estimated). Results are posted in this registry.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

leuprolide (drug) — also listed as: Lupron
letrozole (drug) — also listed as: Femara
zoledronic acid (drug) — also listed as: Zometa

Where the study takes place — 4 listed sites

University of Colorado
Denver, Colorado, United States
Site recruitment: Not reported
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
Site recruitment: Not reported
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Site recruitment: Not reported
Newton Wellesley Hospital
Newton, Massachusetts, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3TerminatedINTERVENTIONAL

Implant and External Radiation for Prostate Cancer With or Without Hormonal Therapy: A Prospective Randomized Trial

ClinicalTrials.gov · NCT00243646 · Registry updated: 2016-04-14

Condition / research focus: Prostate Cancer
Sponsor: Schiffler Cancer Center
Countries with listed sites: United States
Registry dates and results: Start: 2004-08. Completion: 2009-07 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

External beam radiation (radiation)
Lupron (drug)
Casodex (drug)

Where the study takes place — 3 listed sites

Seattle Prostate Institute
Seattle, Washington, United States
Site recruitment: Not reported
Groupe Health Cooperative, Veterans Adminstration Hospital and University of Washington
Seattle, Washington, United States
Site recruitment: Not reported
Schiffler Cancer Center
Wheeling, West Virginia, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Rapid Hormonal Cycling as Treatment for Patients With Prostate Cancer: The Men's Cycle

ClinicalTrials.gov · NCT00586898 · Registry updated: 2016-03-25

Condition / research focus: Prostate; Cancer; Hormonal Cycling
Sponsor: Memorial Sloan Kettering Cancer Center
Countries with listed sites: United States
Registry dates and results: Start: 2001-07. Completion: 2009-03 (may be estimated). Results are posted in this registry.

Products and interventions (5)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

GnRH (drug) — also listed as: LUPRON, ZOLADEX
Ketoconazole (drug) — also listed as: Nizoral
Bicalutamide (drug) — also listed as: Casodex
Testosterone transdermal gel (drug) — also listed as: Androgel
Estrogen transdermal patch (drug) — also listed as: CLIMARA

Where the study takes place — 1 listed sites

Memorial Sloan Kettering Cancer Center
New York, New York, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2TerminatedINTERVENTIONAL

Study of Abraxane Plus Hormonal Therapy as Initial Treatment of Unresectable or Metastatic Prostate Cancer

ClinicalTrials.gov · NCT00521781 · Registry updated: 2016-03-17

Condition / research focus: Prostatic Neoplasms
Sponsor: The Methodist Hospital Research Institute
Countries with listed sites: United States
Registry dates and results: Start: 2007-08. Completion: 2008-10 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Abraxane (drug)
Leuprolide (drug) — also listed as: Depot Lupron®, LHRH agonist
Bicalutamide (drug) — also listed as: Casodex®, Anti-androgen therapy

Where the study takes place — 1 listed sites

Baylor College of Medicine - Methodist Hospital
Houston, Texas, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2 / Phase 3TerminatedINTERVENTIONAL

External Beam Radiation With or Without Chemotherapy to Treat High Risk Prostate Cancer

ClinicalTrials.gov · NCT01603420 · Registry updated: 2016-03-14

Condition / research focus: Prostate Cancer
Sponsor: Proton Collaborative Group
Countries with listed sites: United States
Registry dates and results: Start: 2012-07. Completion: 2014-05 (may be estimated). Results are posted in this registry.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Luteinizing hormone-releasing hormone (LHRH) (drug) — also listed as: -Androgen Suppression, -Androgen Deprivation, -Zoladex, -Lupron, -Eligard, -Viadur
Docetaxel (drug) — also listed as: -taxotere, -docetaxel
Conformal Radiation Therapy (RT) (other) — also listed as: Intensity-modulated Radiation Therapy (IMRT), Proton Therapy, Particle Therapy

Where the study takes place — 3 listed sites

CDH Proton Center
Warrenville, Illinois, United States
Site recruitment: Not reported
Procure Proton Therapy Center
Oklahoma City, Oklahoma, United States
Site recruitment: Not reported
Hampton University Proton Therapy Institute
Hampton, Virginia, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Effect of Increased Circulating Androgens on Granulosa Cell Responses to FSH.

ClinicalTrials.gov · NCT02389088 · Registry updated: 2016-03-10

Condition / research focus: Polycystic Ovary Syndrome
Sponsor: University of California, San Diego
Countries with listed sites: No country reported
Registry dates and results: Start: 2006-04. Completion: 2013-01 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Letrozole (drug) — also listed as: Femora

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Leuprorelin Acetate SR 11.25 mg for Injection Specified Drug-use Survey "Long-term Use Survey on Premenopausal Breast Cancer Patients (96 Weeks)"

ClinicalTrials.gov · NCT02154139 · Registry updated: 2016-02-17

Condition / research focus: Breast Cancer
Sponsor: Takeda
Countries with listed sites: No country reported
Registry dates and results: Start: 2005-12. Completion: 2010-03 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Leuprorelin acetate (drug) — also listed as: Leuplin SR 11.25 mg for Injection

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Pazopanib Hydrochloride After Leuprolide Acetate or Goserelin Acetate in Treating Patients With Relapsed Prostate Cancer

ClinicalTrials.gov · NCT00454571 · Registry updated: 2016-02-10

Condition / research focus: Recurrent Prostate Cancer
Sponsor: National Cancer Institute (NCI)
Countries with listed sites: United States
Registry dates and results: Start: 2006-06. Completion: 2010-12 (may be estimated). Results are posted in this registry.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

pazopanib hydrochloride (drug) — also listed as: GW786034B, Votrient
leuprolide acetate (drug) — also listed as: Enantone, LEUP, Lupron, Lupron Depot
goserelin acetate (drug) — also listed as: ICI-118630, ZDX, Zoladex

Where the study takes place — 2 listed sites

University of Chicago Comprehensive Cancer Center
Chicago, Illinois, United States
Site recruitment: Not reported
University of Wisconsin Hospital and Clinics
Madison, Wisconsin, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

A Phase 3 Comparative Study of TAP-144-SR(6M) in Postoperative and Hormone Therapy-naïve Patients With Premenopausal Breast Cancer

ClinicalTrials.gov · NCT01546649 · Registry updated: 2015-11-26

Condition / research focus: Premenopausal Breast Cancer
Sponsor: Takeda
Countries with listed sites: Japan
Registry dates and results: Start: 2012-04. Completion: 2014-12 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

TAP-144-SR(6M) (drug)
TAP-144-SR(3M) (drug)

Where the study takes place — 15 listed sites

Facility not reported
Nagoya, Aichi-ken, Japan
Site recruitment: Not reported
Facility not reported
Fukushima, Fukushima, Japan
Site recruitment: Not reported
Facility not reported
Maebashi, Gunma, Japan
Site recruitment: Not reported
Facility not reported
Ohta-shi, Gunma, Japan
Site recruitment: Not reported
Facility not reported
Sapporo, Hokkaido, Japan
Site recruitment: Not reported
Facility not reported
Isehara-shi, Kanagawa, Japan
Site recruitment: Not reported
Facility not reported
Yokohama, Kanagawa, Japan
Site recruitment: Not reported
Facility not reported
Kumamoto, Kumamoto, Japan
Site recruitment: Not reported
Facility not reported
Kyoto, Kyoto, Japan
Site recruitment: Not reported
Facility not reported
Nigata-shi, Niigata, Japan
Site recruitment: Not reported
Facility not reported
Kurashiki-shi, Okayama-ken, Japan
Site recruitment: Not reported
Facility not reported
Osaka, Osaka, Japan
Site recruitment: Not reported
Facility not reported
Suita-shi, Osaka, Japan
Site recruitment: Not reported
Facility not reported
Kita-adachi-gun, Saitama, Japan
Site recruitment: Not reported
Facility not reported
Shinjuku-ku, Tokyo, Japan
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer

ClinicalTrials.gov · NCT01511874 · Registry updated: 2015-09-23

Condition / research focus: Prostate Cancer
Sponsor: HanAll BioPharma Co., Ltd.
Countries with listed sites: South Korea
Registry dates and results: Start: 2011-01. Completion: 2013-12 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

ELIGARD 22.5mg (drug) — also listed as: ELIGARD

Where the study takes place — 1 listed sites

Department of Urology,Yonsei University,College of Medicine, Gangnam Severance Hospital
Seoul, South Korea
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Treatment of Hot Flushes Caused by Leuprorelin 11.25 mg in Prostate Adenocarcinoma

ClinicalTrials.gov · NCT01011751 · Registry updated: 2015-07-30

Condition / research focus: Adenocarcinoma, Prostate
Sponsor: Takeda
Countries with listed sites: France
Registry dates and results: Start: 2004-04. Completion: 2007-12 (may be estimated). No results posted in this registry response.

Products and interventions (6)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Cyproterone acetate (drug) — also listed as: Androcur® 50 mg
Medroxyprogesterone acetate (drug) — also listed as: Gestoral® 10 mg
Venlafaxine (drug) — also listed as: Effexor® LP 37.5 mg
Leuprorelin (drug) — also listed as: Enantone® 11.25 mg
Flutamide (drug)
Placebo (drug)

Where the study takes place — 1 listed sites

Professor Jacques IRANI
Poitiers, Poitiers, France
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Leuprorelin Associated With Radiotherapy Versus Leuprorelin Alone in T3 - T4 or pT3 (on Biopsy) N0, M0 Prostate Cancer

ClinicalTrials.gov · NCT01122121 · Registry updated: 2015-07-29

Condition / research focus: Prostatic Neoplasms, Locally Advanced
Sponsor: Takeda
Countries with listed sites: France
Registry dates and results: Start: 2000-03. Completion: 2009-06 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Leuprorelin SR (drug) — also listed as: ENANTONE SR
Radiotherapy (radiation)
Flutamide (drug)

Where the study takes place — 1 listed sites

Clinique Mutualiste
Saint-Etienne, France
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Intermittent Hormonal Therapy With Leuprorelin and Flutamide in the Treatment of Stage D2 or TxNxM1b,c

ClinicalTrials.gov · NCT00817739 · Registry updated: 2015-07-29

Condition / research focus: Prostatic Neoplasms
Sponsor: Takeda
Countries with listed sites: No country reported
Registry dates and results: Start: 1996-12. Completion: 2008-12 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Leuprorelin (drug)
Flutamide (drug)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

A Phase 3 Comparative Study of TAP-144-SR(6M) in Prostate Cancer Patients Previously Treated With Hormonal Therapy

ClinicalTrials.gov · NCT01546623 · Registry updated: 2015-07-21

Condition / research focus: Prostate Cancer
Sponsor: Takeda
Countries with listed sites: Japan
Registry dates and results: Start: 2012-03. Completion: 2014-04 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

TAP-144-SR(6M) (drug)
TAP-144-SR(3M) (drug)

Where the study takes place — 16 listed sites

Facility not reported
Nagoya, Aichi-ken, Japan
Site recruitment: Not reported
Facility not reported
Chiba, Chiba, Japan
Site recruitment: Not reported
Facility not reported
Fukuoka, Fukuoka, Japan
Site recruitment: Not reported
Facility not reported
Maebashi, Gunma, Japan
Site recruitment: Not reported
Facility not reported
Sapporo, Hokkaido, Japan
Site recruitment: Not reported
Facility not reported
Kanazawa, Ishikawa-ken, Japan
Site recruitment: Not reported
Facility not reported
Yokohama, Kanagawa, Japan
Site recruitment: Not reported
Facility not reported
Sendai, Miyagi, Japan
Site recruitment: Not reported
Facility not reported
Nigata-shi, Niigata, Japan
Site recruitment: Not reported
Facility not reported
Osaka, Osaka, Japan
Site recruitment: Not reported
Facility not reported
Suita-shi, Osaka, Japan
Site recruitment: Not reported
Facility not reported
Ageo-shi, Saitama, Japan
Site recruitment: Not reported
Facility not reported
Kita-adachi-gun, Saitama, Japan
Site recruitment: Not reported
Facility not reported
Shizuoka, Shizuoka, Japan
Site recruitment: Not reported
Facility not reported
Shinjuku-ku, Tokyo, Japan
Site recruitment: Not reported
Facility not reported
tabashi City, Tokyo, Japan
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Explore the world’s study registries

These links open external registries; their records are not merged into the results above. WHO ICTRP provides a broader search across contributing registries. Search the same generic name, aliases and development codes in relevant regions. One multinational study may appear in more than one registry, so compare registration identifiers before counting it twice.

Worldwide

Africa

Pan African Clinical Trial Registry ↗

Americas

Asia

Middle East

Europe

Oceania

Australia / New Zealand — ANZCTR ↗

Registry directory checked October 5, 2026 against the WHO registry network. This is a starting point, not complete coverage of every country or continent. Record availability, language and update schedules vary by registry.

Worldwide Study Finder

Loading registry information…

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find a study

Registry search results

Matching records; showing 20 on this page, newest registry updates first. Search checked 2026-11-08 21:13 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Phase 2CompletedINTERVENTIONAL

Chemotherapy, Hormone Therapy, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer

ClinicalTrials.gov · NCT00016913 · Registry updated: 2016-07-06

Condition / research focus: Prostate Cancer
Sponsor: Alliance for Clinical Trials in Oncology
Countries with listed sites: United States
Registry dates and results: Start: 2001-05. Completion: 2008-05 (may be estimated). Results are posted in this registry.

Products and interventions (5)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

carboplatin (drug)
estramustine (drug)
paclitaxel (drug)
radiation therapy (radiation)
leuprolide or goserelin acetate (drug)

Where the study takes place — 23 listed sites

Lombardi Comprehensive Cancer Center at Georgetown University Medical Center
Washington D.C., District of Columbia, United States
Site recruitment: Not reported
Walter Reed Army Medical Center
Washington D.C., District of Columbia, United States
Site recruitment: Not reported
Greenebaum Cancer Center at University of Maryland Medical Center
Baltimore, Maryland, United States
Site recruitment: Not reported
Veterans Affairs Medical Center - Baltimore
Baltimore, Maryland, United States
Site recruitment: Not reported
UMASS Memorial Cancer Center - University Campus
Worcester, Massachusetts, United States
Site recruitment: Not reported
Saint Luke's Hospital
Chesterfield, Missouri, United States
Site recruitment: Not reported
University Medical Center of Southern Nevada
Las Vegas, Nevada, United States
Site recruitment: Not reported
CCOP - Nevada Cancer Research Foundation
Las Vegas, Nevada, United States
Site recruitment: Not reported
Memorial Sloan-Kettering Cancer Center
New York, New York, United States
Site recruitment: Not reported
Oswego Hospital
Oswego, New York, United States
Site recruitment: Not reported
CCOP - Hematology-Oncology Associates of Central New York
Syracuse, New York, United States
Site recruitment: Not reported
SUNY Upstate Medical University Hospital
Syracuse, New York, United States
Site recruitment: Not reported
Veterans Affairs Medical Center - Syracuse
Syracuse, New York, United States
Site recruitment: Not reported
Community General Hospital of Greater Syracuse
Syracuse, New York, United States
Site recruitment: Not reported
Wayne Memorial Hospital, Incorporated
Goldsboro, North Carolina, United States
Site recruitment: Not reported
Wayne Radiation Oncology
Goldsboro, North Carolina, United States
Site recruitment: Not reported
Lenoir Memorial Cancer Center
Kinston, North Carolina, United States
Site recruitment: Not reported
Wilson Medical Center
Wilson, North Carolina, United States
Site recruitment: Not reported
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University
Columbus, Ohio, United States
Site recruitment: Not reported
Roper St. Francis Cancer Center at Roper Hospital
Charleston, South Carolina, United States
Site recruitment: Not reported
Bon Secours St. Francis Health System
Greenville, South Carolina, United States
Site recruitment: Not reported
CCOP - Greenville
Greenville, South Carolina, United States
Site recruitment: Not reported
Danville Regional Medical Center
Danville, Virginia, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableWithdrawnINTERVENTIONAL

Down-regulated Hormonally Controlled Cycles for Vitrification-warmed Blastocyst Transfers

ClinicalTrials.gov · NCT02238431 · Registry updated: 2016-05-26

Condition / research focus: Pregnancy
Sponsor: Antalya IVF
Countries with listed sites: Turkey (Türkiye)
Registry dates and results: Start: 2014-12. Completion: 2016-06 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Lucrin depot (drug)
OCP (drug)
Natural (other)

Where the study takes place — 1 listed sites

Antalya IVF
Antalya, Antalya, Turkey (Türkiye)
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

Everolimus, Bicalutamide, and Leuprolide Acetate in Treating Patients Undergoing Radiation Therapy For High-Risk Locally Advanced Prostate Cancer

ClinicalTrials.gov · NCT00943956 · Registry updated: 2016-05-25

Condition / research focus: Prostate Cancer
Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle
Countries with listed sites: France
Registry dates and results: Start: 2009-01. Completion: 2012-12 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

bicalutamide (drug)
everolimus (drug)
leuprolide acetate (drug)
external beam radiation therapy (radiation)

Where the study takes place — 1 listed sites

Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle
Montpellier, France
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

COmbining Oral Letrozole and Clomiphene for Ovarian Stimulation (COOL-COS) Associated With Corifollitropin Alfa: a Pilot Study

ClinicalTrials.gov · NCT02448459 · Registry updated: 2016-05-23

Condition / research focus: Infertility
Sponsor: University of Sao Paulo
Countries with listed sites: Brazil
Registry dates and results: Start: 2015-05. Completion: 2016-05 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

COOL-COS (drug) — also listed as: Friendly COS

Where the study takes place — 1 listed sites

Setor de Reprodução Humana - HC-FMRP-USP
Ribeirão Preto, São Paulo, Brazil
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Anastrazole Plus GnRH-agonist in the Treatment of Endometriosis Recurrence

ClinicalTrials.gov · NCT01769781 · Registry updated: 2016-04-27

Condition / research focus: Endometriosis
Sponsor: Centre for Endocrinology and Reproductive Medicine, Italy
Countries with listed sites: Italy
Registry dates and results: Start: 2013-01. Completion: 2015-07 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

anastrazole (drug)
GnRH analog alone (drug)

Where the study takes place — 1 listed sites

Cerm-Hungaria
Rome, Italy
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4TerminatedINTERVENTIONAL

Comparison of Trelstar Versus Lupron or Zoladex in Advanced Prostate Cancer

ClinicalTrials.gov · NCT02749825 · Registry updated: 2016-04-25

Condition / research focus: Prostate Cancer
Sponsor: Pharmatech
Countries with listed sites: United States
Registry dates and results: Start: 2002-09. Completion: 2006-07 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Trelstar (drug) — also listed as: Triptorelin pamoate
Lupron (drug) — also listed as: luprolide acetate for depot suspension
Zoladex (drug) — also listed as: goserelin acetate

Where the study takes place — 11 listed sites

Arizona Urologic Specialists
Tucson, Arizona, United States
Site recruitment: Not reported
Heritage Physician Group - Urology Department
Hot Springs, Arkansas, United States
Site recruitment: Not reported
California Oncology of the Central Valley
Fresno, California, United States
Site recruitment: Not reported
San Bernardino Urological Associates Medical Group
San Bernardino, California, United States
Site recruitment: Not reported
UroSearch
Ocala, Florida, United States
Site recruitment: Not reported
Scott A Slavis, MD, PC
Las Vegas, Nevada, United States
Site recruitment: Not reported
Shaukat M Qureshi, MD
Pennsville, New Jersey, United States
Site recruitment: Not reported
Brooklyn Heights Urology Associates
Brooklyn, New York, United States
Site recruitment: Not reported
Jazrawi-Atallah, P.C.
Brooklyn, New York, United States
Site recruitment: Not reported
Albemarle Urology Clinic, PA
Albemarle, North Carolina, United States
Site recruitment: Not reported
Raj P. Chopra MD, PC
Bloomsburg, Pennsylvania, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Extended Endocrine Therapy for Premenopausal Women With Breast Cancer

ClinicalTrials.gov · NCT00903162 · Registry updated: 2016-04-18

Condition / research focus: Breast Cancer
Sponsor: Dana-Farber Cancer Institute
Countries with listed sites: United States
Registry dates and results: Start: 2009-05. Completion: 2014-09 (may be estimated). Results are posted in this registry.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

leuprolide (drug) — also listed as: Lupron
letrozole (drug) — also listed as: Femara
zoledronic acid (drug) — also listed as: Zometa

Where the study takes place — 4 listed sites

University of Colorado
Denver, Colorado, United States
Site recruitment: Not reported
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
Site recruitment: Not reported
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Site recruitment: Not reported
Newton Wellesley Hospital
Newton, Massachusetts, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3TerminatedINTERVENTIONAL

Implant and External Radiation for Prostate Cancer With or Without Hormonal Therapy: A Prospective Randomized Trial

ClinicalTrials.gov · NCT00243646 · Registry updated: 2016-04-14

Condition / research focus: Prostate Cancer
Sponsor: Schiffler Cancer Center
Countries with listed sites: United States
Registry dates and results: Start: 2004-08. Completion: 2009-07 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

External beam radiation (radiation)
Lupron (drug)
Casodex (drug)

Where the study takes place — 3 listed sites

Seattle Prostate Institute
Seattle, Washington, United States
Site recruitment: Not reported
Groupe Health Cooperative, Veterans Adminstration Hospital and University of Washington
Seattle, Washington, United States
Site recruitment: Not reported
Schiffler Cancer Center
Wheeling, West Virginia, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Rapid Hormonal Cycling as Treatment for Patients With Prostate Cancer: The Men's Cycle

ClinicalTrials.gov · NCT00586898 · Registry updated: 2016-03-25

Condition / research focus: Prostate; Cancer; Hormonal Cycling
Sponsor: Memorial Sloan Kettering Cancer Center
Countries with listed sites: United States
Registry dates and results: Start: 2001-07. Completion: 2009-03 (may be estimated). Results are posted in this registry.

Products and interventions (5)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

GnRH (drug) — also listed as: LUPRON, ZOLADEX
Ketoconazole (drug) — also listed as: Nizoral
Bicalutamide (drug) — also listed as: Casodex
Testosterone transdermal gel (drug) — also listed as: Androgel
Estrogen transdermal patch (drug) — also listed as: CLIMARA

Where the study takes place — 1 listed sites

Memorial Sloan Kettering Cancer Center
New York, New York, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2TerminatedINTERVENTIONAL

Study of Abraxane Plus Hormonal Therapy as Initial Treatment of Unresectable or Metastatic Prostate Cancer

ClinicalTrials.gov · NCT00521781 · Registry updated: 2016-03-17

Condition / research focus: Prostatic Neoplasms
Sponsor: The Methodist Hospital Research Institute
Countries with listed sites: United States
Registry dates and results: Start: 2007-08. Completion: 2008-10 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Abraxane (drug)
Leuprolide (drug) — also listed as: Depot Lupron®, LHRH agonist
Bicalutamide (drug) — also listed as: Casodex®, Anti-androgen therapy

Where the study takes place — 1 listed sites

Baylor College of Medicine - Methodist Hospital
Houston, Texas, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2 / Phase 3TerminatedINTERVENTIONAL

External Beam Radiation With or Without Chemotherapy to Treat High Risk Prostate Cancer

ClinicalTrials.gov · NCT01603420 · Registry updated: 2016-03-14

Condition / research focus: Prostate Cancer
Sponsor: Proton Collaborative Group
Countries with listed sites: United States
Registry dates and results: Start: 2012-07. Completion: 2014-05 (may be estimated). Results are posted in this registry.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Luteinizing hormone-releasing hormone (LHRH) (drug) — also listed as: -Androgen Suppression, -Androgen Deprivation, -Zoladex, -Lupron, -Eligard, -Viadur
Docetaxel (drug) — also listed as: -taxotere, -docetaxel
Conformal Radiation Therapy (RT) (other) — also listed as: Intensity-modulated Radiation Therapy (IMRT), Proton Therapy, Particle Therapy

Where the study takes place — 3 listed sites

CDH Proton Center
Warrenville, Illinois, United States
Site recruitment: Not reported
Procure Proton Therapy Center
Oklahoma City, Oklahoma, United States
Site recruitment: Not reported
Hampton University Proton Therapy Institute
Hampton, Virginia, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Effect of Increased Circulating Androgens on Granulosa Cell Responses to FSH.

ClinicalTrials.gov · NCT02389088 · Registry updated: 2016-03-10

Condition / research focus: Polycystic Ovary Syndrome
Sponsor: University of California, San Diego
Countries with listed sites: No country reported
Registry dates and results: Start: 2006-04. Completion: 2013-01 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Letrozole (drug) — also listed as: Femora

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Leuprorelin Acetate SR 11.25 mg for Injection Specified Drug-use Survey "Long-term Use Survey on Premenopausal Breast Cancer Patients (96 Weeks)"

ClinicalTrials.gov · NCT02154139 · Registry updated: 2016-02-17

Condition / research focus: Breast Cancer
Sponsor: Takeda
Countries with listed sites: No country reported
Registry dates and results: Start: 2005-12. Completion: 2010-03 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Leuprorelin acetate (drug) — also listed as: Leuplin SR 11.25 mg for Injection

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Pazopanib Hydrochloride After Leuprolide Acetate or Goserelin Acetate in Treating Patients With Relapsed Prostate Cancer

ClinicalTrials.gov · NCT00454571 · Registry updated: 2016-02-10

Condition / research focus: Recurrent Prostate Cancer
Sponsor: National Cancer Institute (NCI)
Countries with listed sites: United States
Registry dates and results: Start: 2006-06. Completion: 2010-12 (may be estimated). Results are posted in this registry.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

pazopanib hydrochloride (drug) — also listed as: GW786034B, Votrient
leuprolide acetate (drug) — also listed as: Enantone, LEUP, Lupron, Lupron Depot
goserelin acetate (drug) — also listed as: ICI-118630, ZDX, Zoladex

Where the study takes place — 2 listed sites

University of Chicago Comprehensive Cancer Center
Chicago, Illinois, United States
Site recruitment: Not reported
University of Wisconsin Hospital and Clinics
Madison, Wisconsin, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

A Phase 3 Comparative Study of TAP-144-SR(6M) in Postoperative and Hormone Therapy-naïve Patients With Premenopausal Breast Cancer

ClinicalTrials.gov · NCT01546649 · Registry updated: 2015-11-26

Condition / research focus: Premenopausal Breast Cancer
Sponsor: Takeda
Countries with listed sites: Japan
Registry dates and results: Start: 2012-04. Completion: 2014-12 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

TAP-144-SR(6M) (drug)
TAP-144-SR(3M) (drug)

Where the study takes place — 15 listed sites

Facility not reported
Nagoya, Aichi-ken, Japan
Site recruitment: Not reported
Facility not reported
Fukushima, Fukushima, Japan
Site recruitment: Not reported
Facility not reported
Maebashi, Gunma, Japan
Site recruitment: Not reported
Facility not reported
Ohta-shi, Gunma, Japan
Site recruitment: Not reported
Facility not reported
Sapporo, Hokkaido, Japan
Site recruitment: Not reported
Facility not reported
Isehara-shi, Kanagawa, Japan
Site recruitment: Not reported
Facility not reported
Yokohama, Kanagawa, Japan
Site recruitment: Not reported
Facility not reported
Kumamoto, Kumamoto, Japan
Site recruitment: Not reported
Facility not reported
Kyoto, Kyoto, Japan
Site recruitment: Not reported
Facility not reported
Nigata-shi, Niigata, Japan
Site recruitment: Not reported
Facility not reported
Kurashiki-shi, Okayama-ken, Japan
Site recruitment: Not reported
Facility not reported
Osaka, Osaka, Japan
Site recruitment: Not reported
Facility not reported
Suita-shi, Osaka, Japan
Site recruitment: Not reported
Facility not reported
Kita-adachi-gun, Saitama, Japan
Site recruitment: Not reported
Facility not reported
Shinjuku-ku, Tokyo, Japan
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer

ClinicalTrials.gov · NCT01511874 · Registry updated: 2015-09-23

Condition / research focus: Prostate Cancer
Sponsor: HanAll BioPharma Co., Ltd.
Countries with listed sites: South Korea
Registry dates and results: Start: 2011-01. Completion: 2013-12 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

ELIGARD 22.5mg (drug) — also listed as: ELIGARD

Where the study takes place — 1 listed sites

Department of Urology,Yonsei University,College of Medicine, Gangnam Severance Hospital
Seoul, South Korea
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Treatment of Hot Flushes Caused by Leuprorelin 11.25 mg in Prostate Adenocarcinoma

ClinicalTrials.gov · NCT01011751 · Registry updated: 2015-07-30

Condition / research focus: Adenocarcinoma, Prostate
Sponsor: Takeda
Countries with listed sites: France
Registry dates and results: Start: 2004-04. Completion: 2007-12 (may be estimated). No results posted in this registry response.

Products and interventions (6)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Cyproterone acetate (drug) — also listed as: Androcur® 50 mg
Medroxyprogesterone acetate (drug) — also listed as: Gestoral® 10 mg
Venlafaxine (drug) — also listed as: Effexor® LP 37.5 mg
Leuprorelin (drug) — also listed as: Enantone® 11.25 mg
Flutamide (drug)
Placebo (drug)

Where the study takes place — 1 listed sites

Professor Jacques IRANI
Poitiers, Poitiers, France
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Leuprorelin Associated With Radiotherapy Versus Leuprorelin Alone in T3 - T4 or pT3 (on Biopsy) N0, M0 Prostate Cancer

ClinicalTrials.gov · NCT01122121 · Registry updated: 2015-07-29

Condition / research focus: Prostatic Neoplasms, Locally Advanced
Sponsor: Takeda
Countries with listed sites: France
Registry dates and results: Start: 2000-03. Completion: 2009-06 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Leuprorelin SR (drug) — also listed as: ENANTONE SR
Radiotherapy (radiation)
Flutamide (drug)

Where the study takes place — 1 listed sites

Clinique Mutualiste
Saint-Etienne, France
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Intermittent Hormonal Therapy With Leuprorelin and Flutamide in the Treatment of Stage D2 or TxNxM1b,c

ClinicalTrials.gov · NCT00817739 · Registry updated: 2015-07-29

Condition / research focus: Prostatic Neoplasms
Sponsor: Takeda
Countries with listed sites: No country reported
Registry dates and results: Start: 1996-12. Completion: 2008-12 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Leuprorelin (drug)
Flutamide (drug)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

A Phase 3 Comparative Study of TAP-144-SR(6M) in Prostate Cancer Patients Previously Treated With Hormonal Therapy

ClinicalTrials.gov · NCT01546623 · Registry updated: 2015-07-21

Condition / research focus: Prostate Cancer
Sponsor: Takeda
Countries with listed sites: Japan
Registry dates and results: Start: 2012-03. Completion: 2014-04 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

TAP-144-SR(6M) (drug)
TAP-144-SR(3M) (drug)

Where the study takes place — 16 listed sites

Facility not reported
Nagoya, Aichi-ken, Japan
Site recruitment: Not reported
Facility not reported
Chiba, Chiba, Japan
Site recruitment: Not reported
Facility not reported
Fukuoka, Fukuoka, Japan
Site recruitment: Not reported
Facility not reported
Maebashi, Gunma, Japan
Site recruitment: Not reported
Facility not reported
Sapporo, Hokkaido, Japan
Site recruitment: Not reported
Facility not reported
Kanazawa, Ishikawa-ken, Japan
Site recruitment: Not reported
Facility not reported
Yokohama, Kanagawa, Japan
Site recruitment: Not reported
Facility not reported
Sendai, Miyagi, Japan
Site recruitment: Not reported
Facility not reported
Nigata-shi, Niigata, Japan
Site recruitment: Not reported
Facility not reported
Osaka, Osaka, Japan
Site recruitment: Not reported
Facility not reported
Suita-shi, Osaka, Japan
Site recruitment: Not reported
Facility not reported
Ageo-shi, Saitama, Japan
Site recruitment: Not reported
Facility not reported
Kita-adachi-gun, Saitama, Japan
Site recruitment: Not reported
Facility not reported
Shizuoka, Shizuoka, Japan
Site recruitment: Not reported
Facility not reported
Shinjuku-ku, Tokyo, Japan
Site recruitment: Not reported
Facility not reported
tabashi City, Tokyo, Japan
Site recruitment: Not reported

Original record, eligibility, contacts and results →